We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
Read MoreHide Full Article
Shares of CTI BioPharma Corp. plunged 43.4% after the company announced the outcome of a Type B meeting with the FDA, discussing a regulatory pathway for its lead pipeline candidate pacritinib. Per the FDA’s request, the company will have to conduct a phase III study on patients with myelofibrosis.
The news comes as a major setback for investors as it implies additional cost for the company along with a delay in potential approval.
In fact, so far this year, CTI Biopharma stock has lost 15.7% against the industry’s increase of 3.3%.
Pacritinib, an investigational oral kinase inhibitor, is being evaluated in a phase II PAC203 trial for the treatment of myelofibrosis. PAC203 program is expected to complete enrollment by the end of 2018 with full top-line data expected in the second quarter of 2019.
The dosing for the phase III study will be determined based on the results of the PAC203 study. The new phase III study is expected to open in 2019.
The company anticipates the new study to address the unmet medical needs of patients suffering myelofibrosis, primarily for those with severe thrombocytopenia. The company plans to request an additional meeting with the FDA, after the second interim analysis, to discuss interim data from PAC203 trial along with the design of the new phase III study.
In June, the Independent Data Monitoring Committee (IDMC) reviewed the PAC203 study and a second interim review is scheduled during the third quarter of 2018. The study is evaluating the safety and efficacy of three dosing schedules (100 mg once daily, 100 mg twice daily and 200 mg twice daily) over 24 weeks (n=150) on patients with myelofibrosis, previously treated with Incyte Corporation’s (INCY - Free Report) Jakafi (ruxolitinib).
We remind investors that in February 2016, the FDA had placed the company’s Investigational New Drug application for pacritinib on a full clinical hold. However, the FDA removed the same in January 2017.
CTI BioPharma currently has a Zacks Rank #4 (Sell).
AcelRx’ loss per share estimates have been narrowed by 13.2% for 2018 and 23.5% for 2019 over the past 60 days. The stock has soared 43.3% so far this year.
BioLineRx’s loss per share estimates have been narrowed by 16.1% for 2018 and 15.1% for 2019 over the past 60 days.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
Image: Bigstock
CTI BioPharma Tanks Post Type B Talks on Pacritinib With FDA
Shares of CTI BioPharma Corp. plunged 43.4% after the company announced the outcome of a Type B meeting with the FDA, discussing a regulatory pathway for its lead pipeline candidate pacritinib. Per the FDA’s request, the company will have to conduct a phase III study on patients with myelofibrosis.
The news comes as a major setback for investors as it implies additional cost for the company along with a delay in potential approval.
In fact, so far this year, CTI Biopharma stock has lost 15.7% against the industry’s increase of 3.3%.
Pacritinib, an investigational oral kinase inhibitor, is being evaluated in a phase II PAC203 trial for the treatment of myelofibrosis. PAC203 program is expected to complete enrollment by the end of 2018 with full top-line data expected in the second quarter of 2019.
The dosing for the phase III study will be determined based on the results of the PAC203 study. The new phase III study is expected to open in 2019.
The company anticipates the new study to address the unmet medical needs of patients suffering myelofibrosis, primarily for those with severe thrombocytopenia. The company plans to request an additional meeting with the FDA, after the second interim analysis, to discuss interim data from PAC203 trial along with the design of the new phase III study.
In June, the Independent Data Monitoring Committee (IDMC) reviewed the PAC203 study and a second interim review is scheduled during the third quarter of 2018. The study is evaluating the safety and efficacy of three dosing schedules (100 mg once daily, 100 mg twice daily and 200 mg twice daily) over 24 weeks (n=150) on patients with myelofibrosis, previously treated with Incyte Corporation’s (INCY - Free Report) Jakafi (ruxolitinib).
We remind investors that in February 2016, the FDA had placed the company’s Investigational New Drug application for pacritinib on a full clinical hold. However, the FDA removed the same in January 2017.
CTI BioPharma currently has a Zacks Rank #4 (Sell).
Two better-ranked stocks in the same sector are AcelRx Pharmaceuticals, Inc. and BioLineRx Ltd. , both carrying a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
AcelRx’ loss per share estimates have been narrowed by 13.2% for 2018 and 23.5% for 2019 over the past 60 days. The stock has soared 43.3% so far this year.
BioLineRx’s loss per share estimates have been narrowed by 16.1% for 2018 and 15.1% for 2019 over the past 60 days.
Today's Stocks from Zacks' Hottest Strategies
It's hard to believe, even for us at Zacks. But while the market gained +21.9% in 2017, our top stock-picking screens have returned +115.0%, +109.3%, +104.9%, +98.6%, and +67.1%.
And this outperformance has not just been a recent phenomenon. Over the years it has been remarkably consistent. From 2000 - 2017, the composite yearly average gain for these strategies has beaten the market more than 19X over. Maybe even more remarkable is the fact that we're willing to share their latest stocks with you without cost or obligation.
See Them Free>>